trending Market Intelligence /marketintelligence/en/news-insights/trending/70PhbiabSVR7QWRofF3zGw2 content esgSubNav
In This List

Egalet's abuse-deterrent opioid meets main goal in phase 3 trial

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Egalet's abuse-deterrent opioid meets main goal in phase 3 trial

Egalet Corp. said its abuse-deterrent opioid, Egalet-002, met its main goal in a phase 3 study.

Under the trial, the extended-release oxycodone showed a statistically significant difference in average pain intensity from baseline to week 16 compared to placebo in opioid-experienced and opioid-naïve patients with moderate-to-severe chronic low back pain.

The study is the second of two phase 3 studies evaluating Egalet-002. Under the previously announced phase 3 safety study, the treatment was generally well tolerated and no new safety concerns were identified.